TESARO Announces Fourth Quarter and Year-End 2012 Operating Results

TESARO Announces Fourth Quarter and Year-End 2012 Operating Results

[at noodls] – Niraparib to be Advanced in a Phase 3 Pivotal Trial for Ovarian Cancer Enrollment Continues in the Global Registration Program for Rolapitant Achieved Third Dose-level in a Phase 1/2 Clinical Trial of … more

View todays social media effects on TSRO

View the latest stocks trending across Twitter. Click to view dashboard

See who TESARO is hiring next, click here to view

Share this post